Potential of regulatory T-cell-based therapies in the management of severe COVID-19

In view of dysregulated immune response, “cytokine storm” and inflammation-induced lung damage in severely ill COVID-19 patients, we propose that CD4(+)CD25(+)FoxP3(+) regulatory T-cell-based therapies could be considered for patient management https://bit.ly/3eKqWPo